Table 1 Baseline characteristics of the study population
TSR-low | TSR-high | p-value | |
|---|---|---|---|
Age* | 72 (65–80) | 73 (65–77) | 0.743 |
Gender, n (%) | 0.864 | ||
Male | 77 (53.8) | 32 (55.2) | |
Female | 66 (46.2) | 26 (44.8) | |
Comorbidities#, n (%) | 0.402 | ||
0 | 35 (35.7) | 15 (38.4) | |
1 | 31 (31.6) | 10 (25.6) | |
≥ 2 | 32 (32.7) | 14 (35.9) | |
Surgery, n (%) | 0.103 | ||
Elective | 137 (95.8) | 51 (87.9) | |
Acute | 6 (4.2) | 7 (12.1) | |
Tumour localisation, n (%) | 0.845 | ||
Right colon | 74 (51.7) | 31 (53.4) | |
Left colon | 66 (46.2) | 26 (44.8) | |
pT-stage, n (%) | ─ | ||
T1 | 4 (2.8) | 0 (0.0) | |
T2 | 18 (12.6) | 8 (13.8) | |
T3 | 121 (84.6) | 49 (84.5) | |
T4 | 0 (0.0) | 1 (1.7) | |
TNM stage, n (%) | 0.774 | ||
I | 22 (15.4) | 8 (13.8) | |
II | 121 (84.6) | 50 (86.2) | |
Differentiation, n (%) | 0.816 | ||
Well/Moderate | 124 (86.7) | 51(87.9) | |
Poor/Undifferentiated | 19 (13.3) | 7 (12.1) | |
Lymph-angio invasion, n (%) | 0.023 | ||
No | 123 (86.0) | 42 (72.4) | |
Yes | 20 (14.0) | 16 (27.6) | |
BRAF, n (%) | 0.721 | ||
Wildtype (wt) | 117 (82.4) | 49 (84.5) | |
Mutant (mt) | 25 (17.6) | 9 (15.5) | |
KRAS, n (%) | 0.251 | ||
Wildtype (wt) | 88 (61.5) | 40 (70.2) | |
Mutant (mt) | 55 (38.5) | 17 (29.8) | |
Microsatellite, n (%) | 0.685 | ||
Stable (MSS) | 113 (80.1) | 45 (77.6) | |
Instable (MSI) | 28 (19.9) | 13 (22.4) |